A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: March 12, 2007
Last updated: NA
Last verified: March 2007
History: No changes posted

March 12, 2007
March 12, 2007
October 2006
Not Provided
  • To determine the absolute bioavailability of mannitol powder for inhalation by comparison to mannitol administered intravenously.
  • To determine the relative bioavailability of mannitol powder for inhalation by comparison to orally administered mannitol.
  • To determine the pharmacokinetic parameters of systemically available mannitol after administration of mannitol powder by inhalation.
Same as current
No Changes Posted
A secondary objective of the study is to provide information on the urinary excretion of mannitol after each of the routes of administration.
Same as current
Not Provided
Not Provided
A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects
Not Provided

The study has an open-label, randomized, crossover design, in which each subject will receive mannitol powder for inhalation using a dry powder inhaler with and without premedication with a bronchodilator, mannitol powder for inhalation in capsules administered orally, and mannitol in a commercial formulation designed for intravenous use.

Not Provided
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy Volunteers
Drug: Mannitol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2006
Not Provided

Inclusion Criteria:

  • Subject has signed a written informed consent form.
  • Subject is a normal male volunteer between 18 and 65 years of age.
  • Subject is willing to comply with the procedures of the study and to remain in the clinical unit for the scheduled visits.
  • Subject is willing to abstain from chewing gum for the duration of the study.

Exclusion Criteria:

  • Subject has asthma or other disease affecting the lungs or airways.
  • Subject has a history indicating possible airway hyperresponsiveness.
  • Subject is allergic to mannitol or gelatin or a known intolerance to intravenous mannitol.
  • Subject uses inhaled drugs (legal or illegal).
  • Subject uses oral bronchodilator drugs.
  • Subject has celiac disease, Crohn's disease or other disease affecting intestinal absorption.
  • Subject has renal impairment or other condition that would affect urine collection.
  • Subject's weight deviates by more than 15% from the ideal weight listed for his height in the Metropolitan Life table.
  • Subject is a smoker.
  • Subject has participated in another clinical trial within the past 30 days.
  • Subject has used chewing gum within the past 72 hours.
  • Subject needs to use bisphosphonates, non-steroidal anti-inflammatory agents, or other drugs known to affect intestinal permeability on a chronic basis.
  • Subject has used non-steroidal anti-inflammatory agents within the past 72 hours
18 Years and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Principal Investigator: Andrew Humberstone Nucleus Networks
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP